Reliability of estrogen receptors in predicting response to antiestrogens

ONCOLOGY

Volumn 11, Issue 5 SUPPL. 4, 1997, Pages 14-18

  Valavaara, Ritva ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE;

BREAST CANCER; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; POSTMENOPAUSE; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; TAMOXIFEN; TOREMIFENE;

EID: 0030950881     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Jensen EV, De Sombre ER, Jungblut PW: Estrogen receptors in hormone responsive tissues and tumors, in Wissler RW, Dao TL, Wood Jr S: Endogenous Factors Influencing Host-Tumor Balance, pp 15-30 Chicago, University of Chicago Press, 1969.
2. Terenius L: Selective retention of estrogen isomers in estrogen-dependent breast tumors of rats demonstrated by in vitro methods. Cancer Res 28-328-337, 1968.
3. Knight WA, Livingstone RB, Gregory EJ, et al: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
4. Paterson AHG, Zuck VP, Szafran O, et al: Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol 18:937-943, 1982.
5. McGuire WL, Clark GM, Dressier LG, et al: Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1:19-23, 1986
6. Alexieva-Figush J, van Putten WLJ, Blankenstein MA, et al: The prognostic value and relationship of patient characteristics, estrogen and progesterone receptors, and site of relapse in primary breast cancer. Cancer 51:758-768, 1988.
7. Shek LL, Godolphin W: Survival with breast cancer: The importance of estrogen receptor quantity. Eur J Cancer Clin Oncol 25:243-250, 1989.
8. Stewart JF, King RJB, Sexton SA, et al: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449-453, 1981.
9. Howell A, Barnes DM, Harland RNL, et al: Steroid hormone receptors and survival after first relapse in breast cancer Lancet 1:588-591, 1984.
10. Alanko A, Heinonen E, Scheinin T, et al: Significance of estrogen and progesterone receptors, disease free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696-1700, 1985.
11. Clark GM, Sledge GW, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5:55-61, 1987.
12. Kamby C, Rasmussen BB, Kristensen B: Oestrogen receptor status of primary breast carcinomas and their metastases: Relation to pattern of spread and survival after recurrences Br J Cancer 60:252-257, 1989.
13. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
14. Jensen EV, Block GE, Smith S, et al: Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34:55-70, 1971.
15. Osborne CK, Yochmowitz MG, Knight III WA, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer Cancer 46:2884-2888, 1980.
16. Wittliff JL: Steroid hormone receptors in breast cancer. Cancer 53:630-643, 1984.
17. Bonomi P, Gale M, Von Roenn J, et al: Quantitative estrogen and progesterone receptor levels related to progression free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol 15:26-33, 1988.
18. Honig SF: Hormonal therapy and chemotherapy, in Harris JR, Lippman ME, Morrow M, et al: Diseases of the Breast, p 669. Philadelphia, Lippincott-Raven, 1996.
19. Fisher B, Wickerham DH, Redmond C: Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer. Semin Oncol 19:263-277, 1992.
20. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-85, 1992.
21. Goldhirsch A, Gelber RD, Price KM, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-383, 1994.
22. Valavaara R, Kangas L: The significance of estrogen receptors in tamoxifen and toremifene therapy. Ann Clin Res 20:380-388, 1988.
23. Valavaara R, Tuominen J, Johansson R: Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer 66:2264-2269, 1990.
24. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556-2566, 1995
25. Glass AG, Hoover RN: Rising incidence of breast cancer: Relationship to stage and receptor status. J Natl Cancer Inst 82:693-696, 1990.
26. Di Fronzo G, Coradini D, Capelletti V, et al: Hormone receptors and disease free survival in breast cancer: Impact of increasing threshold levels. Anticancer Res 10:1699-1706, 1990.
27. Pujol P, Hilsenbeck SG, Chamness GC, et al: Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74:1601-1606, 1994.
28. Korenman SG: Comparative binding of estrogens and its relation to estrogenic potency. Steroids 13:163-178, 1969
29. Clark GC, Osborne CK, McGuire WL: Correlations between estrogen receptor and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109, 1984.
30. Klemi PJ, Joensuu H, Toikkanen S, et al: Aggressiveness of breast cancers found with and without screening. Br Med J 304:467-469, 1992.
31. Pertschuk LP, Feldman JG, Kim YD, et al: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp in frozen sections or cytosol-based ligand-binding assays Cancer 77:2514-2519, 1996.
32. Alberts SR, Ingle JN, Roche PR, et al: Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764-772, 1996.
33. Fernö M, Borg U, Johansson U, et al: Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. Acta Oncol 29:129-135, 1990.
34. Thorpe SM: Estrogen and progesterone receptor determinations in breast cancer. Acta Oncol 27:1-19, 1988.
35. Helin HJ, Helle MJ, Kallioniemi OP, et al: Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Cancer 63:1761-1767, 1989.
36. Paradiso A, Lorusso V, Tommasi S, et al: Relevance of cell kinetics to hormonal response of receptor positive advanced breast cancer. Breast Cancer Res Treat 11:31-36, 1988.
37. Vihko R, Jänne O, Kontula K, et al: Female sex steroid receptor status in primary and metastatic breast carcinoma and its relationship to serum steroid and peptide hormone levels. Int J Cancer 26:13-21, 1980.
38. Kuukasjärvi T, Kononen J, Helin H, et al: Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14:2584-2589, 1996.
39. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995
40. Fuqua SA: Estrogen receptor mutagenesis and hormonal resistance. Cancer 74:1026-1029, 1994.
41. Jordan VC, Dix CJ, Naylor KE, et al: Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of action. J Toxicol Environ Health 4:363-390, 1978.
42. Kallio S, Kangas L, Blanco G, et al: A new triphenylethylene compound, Fc-1157a: I. Hormonal effects. Cancer Chemother Pharmacol 17:103-108, 1986.
43. Rochefort H: Mechanism of action of high-affinity antiestrogens. Am J Clin Oncol 14(suppl 2):1-4, 1991.
44. Valavaara R, Tuominen J, Toivanen A: The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother 31:381-386, 1990.
45. Paavonen T, Anderson LC: The estrogen antagonists, tamoxifen and FC-1157a display estrogen like effects on human lymphocyte functions in vitro. Clin Exp Immunol 61:467-469, 1985.
46. Wärri AM, Huovinen RL, Laine AM, et al: Apoptosis in torermifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85:1412-1418, 1993.
47. Huovinen R, Wärri A, Collan Y: Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 55:685-691, 1993.
48. Kangas L, Nieminen A-L, Blanco G, et al: A new triphenylethylene compound, Fc-1157a. II: Antitumor effects. Cancer Chemother Pharmacol 17:109-113, 1986.
49. Perry JJ, Berry DA, Weiss RB, et al: High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: A phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat 36 (1):35-40, 1995.